Different factors have been proposed to explain the higher efficacy of polatuzumab in the ABC-type DLBCL, including a potential inhibition of BCR signaling through CD79b internalization by polatuzumab binding, taking into account the greater dependency on BCR in ABC DLBCL. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.